News

The study is a 19-week follow-up, multicentre, double-blind, randomised, placebo-controlled, parallel-group study in subjects with MS spasticity not fully relieved with current anti-spasticity therapy. The trial result suggested

Nektar has posted a net loss of $22.58m for the fourth quarter of 2010, compared to net loss $7.68m for the same period in 2009.The company’s loss from

L-DOS47 is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic NSCLC. According to Helix, L-DOS47 will stimulate an increase

ERT has posted gross margin of $19.71m for the fourth quarter of 2010, compared to $13.17m for the same period in 2009. The company has generated net income

The 28 February 2011 deal will add four Catalent sites (in Ireland, the US and Puerto Rico) with sales of more than $100m to Clondalkin’s network of 14

Bavarian Nordic said the multicentre, randomised Phase II study will compare Prostvac followed by docetaxel (chemotherapy) versus docetaxel alone. Patients in the Prostvac arm will receive an accelerated

The dose-escalation Phase I trial will evaluate the safety profile, pharmacokinetics and antitumour activity of brentuximab vedotin when administered sequentially or in combination with multi-agent front-line chemotherapy regimens.

The companies filed the lawsuit in the US District Court for the Southern District of New York and the US District Court for the District of Vermont. Reportedly,

Cenicriviroc (TBR-652) is a potent antagonist of CCR5, a co-receptor needed for HIV infection, and CCR2, another co-receptor prominently involved in several metabolic and cardiovascular diseases. Findings have